EicOsis has received USD 15Million grant from the National Institute of Drug Abuse (NIDA) to fund the clinical trials of non-opioid pain therapy. NIDA, with an…
Category: The Business Cocktail
Oct 15 
ImaginAb joins hands with AZ, Pfizer, Takeda; FDA okays Akorn’s betamethasone lotion; Aytu Bio signs an asset purchase agreement with Cerecor
ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells. ImaginAb is an emerging imaging company…
Oct 10 
First oral GLP-1 treatment approved for type2 Diabetes; GSK collaborates with Lyell to develop cancer therapies; Beovu receives FDA approval to treat wet AMD
The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. Rybelsus is an oral glucagon-like peptide…
Oct 8 
AngioDynamics acquires Eximo; MiroBio raises USD 33 M; Janssen submits sBLA for Stelara
AngioDynamics, an innovative medical devices provider, has signed an upfront USD 46 Million deal to acquire Eximo Medical. AngioDynamics is a leading player in manufacturing medical…
Oct 3 
Roche’s Tecentriq combo proves effective in Bladder cancer; Sobi buys Dova pharmaceuticals; Cheplapharm purchases Losec
Roche’s Genentech has presented positive Phase III results from the IMvigor130 study aimed at studying Tecentriq (atezolizumab) tested in combination with platinum-based chemotherapy. The drug, Tecentriq,…
Oct 1 
STipe raises USD 22M; FDA approves Darzalex combo for multiple myeloma patients; Sanofi launches Suliqua in the UK
Stipe Therapeutics (STipe) has raised USD 22 Million to move forward its clinical development of novel candidates to target intracellular protein-protein interactions of the STING Pathway….
Sep 26 
EU’s labels Nirogacestat an Orphan drug; FDA Approves First Smallpox, Monkeypox Vaccine; Evotec and Takeda collaborates to discover clinical candidates
European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma. Nirogacestat is a selective oral small molecule, gamma-secretase inhibitor under development…
Sep 24 
Flagship Pioneering launches Omega Therapeutics; EU nod to Vitrakvi; Bluebird Bio reveals positive results of Starbeam clinical trial
Flagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine. The launch of Omega therapeutics was planned to focus on epigenetic…
Sep 19 
Fujifilm acquires global rights to Cynata’s novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop’s digital diabetes platform
FUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop,…
Sep 17 
AlivaMab collaborates with Janssen for antibody discovery; Lundbeck acquires Alder BioPharmaceutical; Helsinn and Mundipharma announce China approval of Akynzeo
AlivaMab Discovery Services (ADS) has announced an antibody discovery agreement against multiple targets with Janssen Research & Developments. AlivaMab, a pharmaceutical providing fully human therapeutic antibody…
